Medical Condition News

RSS

QLT receives exclusive U.S. sales and marketing rights for Visudyne therapy

QLT Inc. ("QLT" or the "Company") today announced that it has restructured its agreement with Novartis Pharma AG ("Novartis") to simplify the relationship, under which, effective January 1, 2010, it will, among other things, receive exclusive U.S. rights to the Visudyne(R) patents to sell and market Visudyne in the U.S. Visudyne, a photosensitizer co-developed with Novartis, is approved worldwide for the treatment of a form of wet age-related macular degeneration ("AMD"), the leading cause of legal blindness in people over the age of 55 in North America and Europe.

19 Oct 2009

Lubricin injections can reduce cartilage degeneration

Medical researchers will report findings today (Oct. 19) that demonstrate that injecting the protein lubricin into knee joints can dramatically reduce cartilage degeneration.

19 Oct 2009

Copper bracelets and magnetic wrist straps are ineffective in relieving arthritis pain, says study

Copper bracelets and magnetic wrist straps are ineffective in relieving arthritis pain, according to a new study led by a University of York academic.

19 Oct 2009

Anti-clotting drug may cause problems for elderly trauma patients: Study

A common drug used for preventing heart attacks and blood clots may also cause problems for individuals who suffer some form of trauma, particularly elderly patients, according to a study presented today at the 2009 Clinical Congress of the American College of Surgeons.

19 Oct 2009

New mathematical model for rapid and accurate diagnoses of AHF

Researchers at St. Michael's Hospital have developed the first mathematical model in cardiology and emergency medicine to more quickly and reliably diagnose acute heart failure (AHF) in emergency room patients

19 Oct 2009

Readmission of elderly patients after colectomy strongly linked with mortality: Study

Readmission to a hospital after standard surgical treatment for colon cancer is far more common than suspected for elderly patients according to researchers who presented their findings at the 2009 Clinical Congress of the American College of Surgeons. Results from the first study to determine nationwide readmission rates following colectomy [surgical removal of malignant disease and part of the colon] in the Medicare population revealed that nearly one in nine patients over the age of 65 was readmitted within 30 days.

19 Oct 2009

NanoBio's NB-401 preclinical data to be presented at the 2009 North American Cystic Fibrosis Conference

NanoBio Corporation today announced compelling preclinical data for NB-401, a nebulized nanoemulsion-based agent that kills highly drug-resistant strains of bacteria commonly found in cystic fibrosis patients. Currently there are limited treatment options available that effectively address these resistant bacteria. The study results are being presented today at the 2009 Annual North American Cystic Fibrosis Conference (NACFC) in Minneapolis, Minn.

19 Oct 2009

Breakthrough discovery by scientists may lead to a new treatment for Alzheimer's Disease

A breakthrough discovery by scientists from the Mayo Clinic in Jacksonville, FL, may lead to a new treatment for Alzheimer's Disease that actually removes amyloid plaques-considered a hallmark of the disease-from patients' brains.

19 Oct 2009

NCCN Clinical Practice Guidelines in Oncology updated to include pralatrexate drug

NCCN has added pralatrexate (Folotyn(TM), Allos Therapeutics, Inc.) to the NCCN Guidelines for Non-Hodgkin's Lymphomas as one of the options for second-line therapy for relapsed or refractory peripheral T-cell lymphoma.

19 Oct 2009

Smoking bans reduce risk of of heart attack in nonsmokers and smokers

Smoking bans are effective at reducing the risk of heart attacks and heart disease associated with exposure to secondhand smoke, says a new report from the Institute of Medicine. The report also confirms there is sufficient evidence that breathing secondhand smoke boosts nonsmokers' risk for heart problems, adding that indirect evidence indicating that even relatively brief exposures could lead to a heart attack is compelling.

19 Oct 2009

Chrysanthemum indicum extract holds promise for treating human cancer

A series of studies have demonstrated that Chrysanthemum indicum possesses antimicrobial, antiinflammatory, immunomodulatory, and neuroprotective effects. Recently, much attention has been devoted to the anticancer activity of Chrysanthemum indicum, especially in hepatocellular carcinoma (HCC). However, its anticancer mechanism of action is still not clear and needs further investigation.

19 Oct 2009

Physical therapists can promote early diagnosis of breast cancer-related lymphedema

As breast cancer awareness month is observed during October, the American Physical Therapy Association (APTA) is hoping to shine a spotlight on lymphedema, a chronic, debilitating and often irreversible side effect of cancer treatment.

19 Oct 2009

Stem cell treatments could repair the kidney defects associated with Alport syndrome

Several cell-based therapy approaches could provide new treatments for patients with Alport syndrome, reports an upcoming paper in the Journal of the American Society of Nephrology (JASN). "Our study opens up many considerations of how new therapies related to the use of stem cells can be devised for our kidney patients with chronic disease," comments Raghu Kalluri, MD, PhD (Harvard Medical School, Boston, MA).

19 Oct 2009

Immune-related proteins are potential drug targets for gastric inflammation and cancer

A research team from South Korea studied the complex reaction of gastric inflammation induced by Helicobacter pylori (H pylori) in a systematic manner using a protein interaction network. Their study will be published on September 28, 2009 in the World Journal of Gastroenterology.

19 Oct 2009

Researchers find the genetic mutation that is linked with changes in brain development

For decades, scientists have thought the faulty neural wiring that predisposes individuals to behavioral disorders like autism and psychiatric diseases like schizophrenia must occur during development. Even so, no one has ever shown that a risk gene for the disease actually disrupts brain development.

19 Oct 2009

New scientific journal from Elsevier

Elsevier, a world-leading publisher of scientific, technical and medical information products and services announced today the launch of a new peer-reviewed scientific journal, Spatial and Spatio-temporal Epidemiology (http://www.elsevier.com/locate/sste).

19 Oct 2009

Angiochem announces results of Phase 1 /2 clinical trials of ANG1005

Angiochem, Inc. a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases, announced today that its lead drug candidate, ANG1005, has demonstrated a favorable safety and efficacy profile in more than 100 patients with brain cancer from two separate Phase 1 /2 clinical studies in patients with progressive gliomas, including recurrent glioblastoma, and in patients with progressive brain metastases.

19 Oct 2009

CONFIRMS trial demonstrates efficacy of ULORIC for treating hyperuricemia in patients with gout

Data presented at the 73rd Annual Scientific Meeting of the American College of Rheumatology highlight effects of baseline characteristics on achievement of serum uric acid (sUA) levels to <6.0 mg/dL and the frequency of flares with ULORIC® (febuxostat) treatment.

19 Oct 2009

$FRAX online tool to help clinicians to better identify women and men at high risk of fracture$

FRAX online tool to help clinicians to better identify women and men at high risk of fracture

The International Osteoporosis Foundation (IOF) will issue a new 16-page report on FRAX- to mark World Osteoporosis Day on October 20, 2009. The report is available at http://www.iofbonehealth.org/publications/frax.html

19 Oct 2009

FDA approves continuation of the fourth 6-month open label extension of PRX-03140

The FDA has approved a Physician-Sponsored IND and continuation of the fourth 6-month open label extension of PRX-03140, a novel 5HT4 partial agonist for the potential treatment of Alzheimer's Disease. The patient was enrolled initially in a two week Phase 2a study in August 2007 where she received 100 mg per day of PRX-03140 in combination with her normal daily dose of Aricept(10 mg).

19 Oct 2009

Medical Condition News

QLT receives exclusive U.S. sales and marketing rights for Visudyne therapy

Lubricin injections can reduce cartilage degeneration

Copper bracelets and magnetic wrist straps are ineffective in relieving arthritis pain, says study

Anti-clotting drug may cause problems for elderly trauma patients: Study

New mathematical model for rapid and accurate diagnoses of AHF

Readmission of elderly patients after colectomy strongly linked with mortality: Study

NanoBio's NB-401 preclinical data to be presented at the 2009 North American Cystic Fibrosis Conference

Breakthrough discovery by scientists may lead to a new treatment for Alzheimer's Disease

NCCN Clinical Practice Guidelines in Oncology updated to include pralatrexate drug

Smoking bans reduce risk of of heart attack in nonsmokers and smokers

Chrysanthemum indicum extract holds promise for treating human cancer

Physical therapists can promote early diagnosis of breast cancer-related lymphedema

Stem cell treatments could repair the kidney defects associated with Alport syndrome

Immune-related proteins are potential drug targets for gastric inflammation and cancer

Researchers find the genetic mutation that is linked with changes in brain development

New scientific journal from Elsevier

Angiochem announces results of Phase 1 /2 clinical trials of ANG1005

CONFIRMS trial demonstrates efficacy of ULORIC for treating hyperuricemia in patients with gout

FRAX online tool to help clinicians to better identify women and men at high risk of fracture

FDA approves continuation of the fourth 6-month open label extension of PRX-03140

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News